Clinical trials: LCIS

Breast Cancer

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

• Active, not recruiting
• Age: 24 to 64 years
• Phase 2/3

Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.

Trial name

Drugs-SNPs (NCT06062810)

Testing

Raloxifene - Usual, Raloxifene - Study

Where

United States

Volunteers

600 people

Sponsor

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair